Afatinib for patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: clinical implications of the LUX-Lung 7 study

Ítems similars

• The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer
  per: Jung, Hyun Ae, et al.
  Publicat: (2020)
• First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the ‘real-world’ clinical setting
  per: Park, Keunchil, et al.
  Publicat: (2019)
• Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
  per: Paz-Ares, L., et al.
  Publicat: (2017)
• Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence
  per: E-E Ke, et al.
  Publicat: (2016-06-01)
• Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence
  per: Ke, E-E, et al.
  Publicat: (2016)